Published Date: 30-Nov-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Head And Neck Cancer Therapeutics Market size is expected to reach $2.5 billion by 2028, rising at a market growth of 12.3% CAGR during the forecast period.
The Targeted Therapy segment is showcasing a CAGR of 12.6% during (2022 - 2028). It is because targeted therapy refers to a treatment that targets the specific genes, proteins, or tissue environment that promotes the growth and survival of cancer. This method of therapy inhibits the development and proliferation of cancer cells while minimizing harm to healthy cells. The targeted treatment has shown promising and beneficial outcomes as a therapeutic option for individuals with head and neck cancer.
The Injectable segment acquired maximum revenue share in the Global Head & Neck Cancer Therapeutics Market by Route of Administration in 2021 thereby, achieving a market value of $2.1 billion by 2028. It is because the new treatments for cancer of the head and neck involve direct injection of the therapeutic substance into the malignant lesions. This locoregional treatment permits the adaption of traditional chemotherapy drugs, to reach larger drug concentrations in the tumor while avoiding significant systemic toxicity.
The Hospital Pharmacies segment has shown the growth rate of 12.7% during (2022 - 2028). In every hospital ward, pharmacists provide a medication reconciliation program for inpatients to improve the quality of therapy and reduce the workload of physicians and nurses. The pharmacist collects, compiles, and maintains a database of medication information and distributes relevant data to the medical personnel. Through paper distribution and/or the in-hospital computer network, drug information is rapidly communicated across the hospital.
The North America market dominated the Global Head & Neck Cancer Therapeutics Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1 billion by 2028. The Europe market is exhibiting a CAGR of 11.6% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 13.4% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Bristol Myers Squibb Company, and Clinigen Group PLC.
By Therapy Type
By Route of Administration
By Distribution Channel
Unique Offerings from KBV Research